To test the safety and immunogenicity of a high-titered preparation of ALVAC-HIV vCP205 in both high-risk and low-risk persons and to evaluate variations in dosing schedule, we conducted a multicenter, randomized, double-blind trial of this vector in combination with recombinant subunit gp120 in 150 HIV-1-seronegative volunteers. The high-titered ALVAC vaccine was well tolerated; adverse events were minimal and not influenced by dosing. At day 728, the cumulative probability of a cytotoxic T-lymphocyte (CTL) response was 76% (95% confidence interval [CI]: 64%-89%) among volunteers receiving vaccine, and the net amount attributable to vaccination was 50% (CI: 16%; 74%). The net probability of a repeated positive CTL response by day 728 was 50% (CI: 21%; 64%). There was a significant difference in CTL response at day 182 between volunteers who had received four doses versus three doses of vCP205 (42% vs. 24%, p = .052). The CTL response was similar in high-risk volunteers and vaccinia-naive volunteers compared with vacciniaimmune volunteers. Neutralizing antibody responses were detected in 95% of vaccinees at day 287, with higher geometric mean titers in recipients of sequential versus simultaneous dosing of the two vaccines and in vaccinia-naive volunteers. This hightitered preparation of ALVAC-HIV vCP205 in combination with gpl20 was safe and immunogenic in a diverse group of HIV-1-seronegative volunteers.
Address correspondence and reprint requests to Lawrence Corey, 1100 Fairview Avenue North (D3-100), Seattle, WA 98109 U.S.A.; email: firstname.lastname@example.org
Manuscript received July 23, 2001; accepted November 10, 2001.
© 2002 Lippincott Williams & Wilkins, Inc.